Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 2026

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumors Additional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented CAMBRIDGE, England — Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the […]


3 d.
Science
ID: -9013281076718081167


Similar News expand_more


Science
Science
Science
Science
Technology
Science
Technology
Science
Science
Science
Science
Science
Science
Technology
Science
Science
Science
Science
Technology
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Culture
Science
Science
Technology
Science
Science
Science
Sport
Politics
Space
Technology
Science
Science
Technology
Science
Science
Culture
Culture
Education
Culture
Popular countries based on strong economic and political relations

Add Watch Country

arrow_drop_down